Professional background

Dr Daniel Marks is a consultant physician with expertise in acute and general medicine, clinical pharmacology, and drug development. Dr Marks studied medicine at University College London, and was awarded a PhD and Wellcome Trust postdoctoral research fellowship for his work on the immunology of Crohn's disease and ulcerative colitis.

He trained in general medicine and clinical pharmacology at University College London Hospitals, during which he developed his sub-specialty interests in drug discovery, clinical toxicology (providing holistic care following accidental or deliberate drug overdose or adverse drug reactions), and looking after patients with difficult diagnostic problems.

Dr Marks has deep expertise in clinical trials and immunotherapeutics and, alongside his role at UCLH, is senior medical director for early clinical development at AstraZeneca, prior to which he was physician director for discovery medicine at GlaxoSmithKline.

Dr Marks also sits on the clinical committee for the British Pharmacological Society, and is an executive editor of the British Journal of Clinical Pharmacology. He is a keen educator, and has received multiple awards for his regular contributions to both undergraduate and postgraduate training.

Research interests

  • Clinical trials
  • Drug discovery
  • Immunotherapeutics
  • Pathogenesis of chronic inflammatory diseases
  • Toxicology


• HALT-IT Trial Collaborators (2020) Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet, 395: 1927-36.
• Ellis J et al (2020) Depletion of LAG-3+ T cells translated to pharmacology and improvement in psoriasis disease activity: a Phase 1 randomised study of mAb GSK2831781. Clin Pharmacol Ther, In press
• Chavda SJ et al (2020) Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations. Br J Haematol, In press
• Slevin S et al (2020) Lymphocyte activation gene (LAG)-3 is associated with mucosal inflammation and disease activity in ulcerative colitis. J Crohn's Colitis, In press
• Wysoczanski R et al (2019) Ulcerative colitis is characterized by amplified acute inflammation with delayed resolution. BioRx
• George MJ et al (2018) Resistant hypertension: trials and tribulations. Hypertension, 71: 772-80
• Marks DJB et al (2017) Outcomes from massive paracetamol overdose: a retrospective observational study. Br J Clin Pharmacol, 83: 1263-72
• Bharucha T et al (2017) Diagnosis yield of FDG-PET/CT in fever of unknown origin: a systemic review, meta-analysis, and Delphi exercise. Clin Radiol, 72: 761-71
• Motwani M et al (2016) Novel translational model of resolving inflammation triggered by UV-killed E. coli. J Path: Clin Res, 2: 154-65
• Marks DJB (2016) Time to halt the overprescibing of proton pump inhibitors. Clin Pharmacist, 8: 226-8
• Marks DJB et al (2015) Clinical features, microbiology and surgical outcomes of infective endocarditis: a 13-year study from a UK tertiary cardiothoracic referral centre. QJM, 108: 219-29
• Owen C et al (2014) The dangers of proton pump inhibitor therapy. Br J Hosp Med, 75: C108-12
• Doshi A et al (2013) Back pain and acute kidney injury. Clin Med, 13: 71-4
• Marks DJB et al (2012) Thoracic empyema: a 12-year study from a UK tertiary cardiothoracic referral centre. PLoS One, 7: e30074
• Fisk M et al (2012). Mycotic aneurysms: a case report, clinical review and novel imaging strategy. QJM, 105: 181-8
• Marks DJB (2011) Defective innate immunity in IBD: a Crohn's disease exclusivity? Curr Opin Gastroenterol, 27: 329-3
• Rahman FZ et al (2010) Aberrant TLR4-mediated macrophage activation results in excessive CXCL10 secretion and delayed resolution of acute inflammation in ulcerative colitis. PLoS One, 5: e9891
• Marks DJB et al (2010) Inflammatory bowel diseases in patients with adaptive and complement immunodeficiency disorders. Inflamm Bowel Dis, 16: 1984-92
• Marks DJB et al (2009) Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am J Gastroenterol, 104: 117-24
• Smith AM et al (2009) Disordered macrophage secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med, 206: 1883-97
• Sewell GW et al (2009) The immunopathogenesis of Crohn's disease: a three stage model. Curr Opin Immunol, 21: 506-13
• Marks DJB et al (2009) Adverse events to anti-tuberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS, 20: 339-45
• Marks DJB & Segal AW (2008) Innate immunity in inflammatory bowel disease: a disease hypothesis. J Pathol, 214: 260-6
• Marks DJB et al (2008) Phagocyte dysfunction and inflammatory bowel disease. Inflamm Bowel Dis, 14: 1443-52
• Marks DJB et al (2007) Impotent immune system: an underlying problem in Crohn's disease. Gastroenterology, 132: 2611
• Marks DJB et al (2007) Modified skin window technique for the extended characterisation of acute inflammation in human subjects. Inflamm Res, 56: 168-74
• Marks DJB et al (2006) Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet, 367: 668-78
• Marks DJB et al (2006) An exuberant inflammatory response to E coli: implications for the pathogenesis of ulcerative colitis and pyoderma gangrenosum. Gut, 55: 1662-3
• Harbord M et al (2006) Impaired neutrophil chemotaxis in Crohn's disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor. Aliment Pharmacol Ther, 24: 651-60
• Robinson M et al (2004) FLRT3 is expressed by sensory neurons after peripheral nerve injury and regulates neurite outgrowth. Mol Cell Neurosci, 27: 202-14
• Daniel Marks is also the author of the Oxford Handbook of Gastroenterology and Hepatology (2nd and 3rd editions), and Emergencies in Gastroenterology and Hepatology (Oxford University Press)